Therapeutic use of VEGF-C and CCBE1

A VEGF-C, CCBE1 technology, applied in gene therapy, medical preparations containing active ingredients, chemical instruments and methods, etc., can solve the problem of no cure for lymphedema

Inactive Publication Date: 2016-06-15
LAURANTIS PHARMA
View PDF2 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0009] Despite great progress in recent years in identifying molecules specifically expressed on lymphatic vessels, there is still no curative therapy available for lymphedema

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic use of VEGF-C and CCBE1
  • Therapeutic use of VEGF-C and CCBE1
  • Therapeutic use of VEGF-C and CCBE1

Examples

Experimental program
Comparison scheme
Effect test

Embodiment

[0068] Materials and methods

[0069] clone. Genes expressed by recombinant adeno-associated virus (rAAV9) vectors were cloned into the psubCAG-WPRE plasmid (Paterna et al., 2000, GeneTherapy (Gene Therapy) 7:1304-1311), which is a derivative of psubCMV-WPRE in which the CMV promoter has been replaced by a composite CAG promoter consisting of the chicken β-actin promoter, cytomegalovirus enhancer and β-actin intron (Okabe et al., 1997 , FEBS Letters 407:313-319). Cloning of full-length mVEGF-C, ΔNΔC-mVEGF-C and HAS into an AAV-vector (psubCAG-WPRE) has been described earlier (Anisimov et al., 2009, supra). mCCBE1 fused to the V5 marker (mCCBE1-V5) was cloned as follows: Part of the coding DNA sequence of CCBE1 (CDS; GenBank #BC152322, image clone ID40140631) was cloned as a SacI / XbaI fragment into pVK1 (pUC19-derived vector ( Anisimov et al., 2007, Molecular Breeding 19:241-253)). Brown adipose tissue mRNA was amplified with primers 5'-GCCGCTAGCGCCACCATGGTGCCGCCGCCT-3' (SE...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to view more

Abstract

The present invention relates to therapeutic methods, us- es and compositions comprising CCBE1 and VEGF-C for treating disorders and conditions involving impaired lym- phatic system, particularly lymphedema.

Description

technical field [0001] The present invention relates to therapeutic methods, uses and compositions for the treatment of diseases (disorders) and conditions (in particular lymphedema) involving a damaged lymphatic system. Background technique [0002] Lymphedema is a chronic disabling and disfiguring disorder of localized lymphatic fluid retention and progressive swelling caused by a dysfunctional lymphatic system. It is a lifelong condition that seriously affects the quality of life of approximately 140 million patients worldwide. [0003] Primary lymphedema is a rare genetic disorder usually caused by abnormal development of lymphatic vessels. Symptoms of primary lymphedema may appear at birth or later in life. [0004] Acquired or secondary lymphedema is caused by damage to the lymphatic system. In Western countries, it is most commonly caused by lymphadenectomy, surgery and / or radiation therapy, in which damage to the lymphatic system is caused during the treatment of ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K38/18A61K38/17A61P7/00A61P7/10
CPCA61K38/1709A61K38/1866A61K38/1738A61P7/10A61K2300/00A61K48/00A61P7/00A61K38/18C12N15/85C12N15/63A61K48/005C07K2319/036
Inventor 卡利·阿里它罗迈克尔·耶尔奇安德烈·阿尼斯姆
Owner LAURANTIS PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap